Typical of these jerks. Talk about dodging a bullet - the recruiter went on and on about why I should leave a great job because this was so hot. Glad I'm not staring at an empty desk, waiting for ZS to reorganize and downsize. Oh yeah, due to a change in strategic direction we are now working in alzheimers.
Intarcia Therapeutics
- Thread starter anonymous
- Start date
-
- Tags
- None
So can you counter the points made by the naysayers? Didn't think so other than call them morons. Get you sorry ass head out of the sand and quit worshiping KG, douchebag.
Responding to your own post? You deserve to work at shithole Intarcia.
Heard that HR and their clueless contract recruiters treated applicants poorly and burnt so many candidates thru idiotic test, arrogant phone screens and in-house interviews last time that they are getting poor responses and often outright scorn especially from the candidates who had gone thru the wringers.
We dont need no FDA approval. Shut up about stupid reimbursement. Everyone will want da pump. Its just like tattoos super cool super popular. Tattoos are good for life. Just like the scars from shoving the pump in and then ripping it out. Cute little scars that say super cool super popular. Hey cutting is cool.
Yeah the dumb as nail pts are proud of walking around with matchstick POS protruding out of their bloated tummies. That is if this POS ever gets approved and especially the payors cover the cost - ain't gonna happen.
In the mean time Intarcia has enough money in the bank till end of 2018 and will have to beg and more like extort more money from the bagholders to launch.
Senior Global Product Manager in Patient strategy for Oral Semaglutide
We are looking for a dedicated Senior Global Product Manager to be part of our newly established Oral Semaglutide team. Do you want to be the voice of the patient and to develop our patient strategy? About the department The Oral semaglutide team is part of the GLP-1 Portfolio Corporate Vice President (CVP) area in Strategy, Access & Marketing in Novo Nordisk. Oral semaglutide represents a unique opportunity for Novo Nordisk to enter the large and competitive Oral Anti-diabetic (OAD) market with a product supported by a unique clinical profile. Ahead of the phase III data results in 2018, the oral semaglutide is expanding in preparation of the launch. The position The selected candidate will be the voice of the patient in the Oral Semaglutide team. The candidate will be responsible for developing the patient strategy and tactics for oral semaglutide including product acceptance and experience. This will include definition of patient needs and development of the patient activation strategic framework including patient behavioural segmentation. Further to this, the responsibility in this role will include patient communication strategy and tactics and identification of patient solutions and tools to support product experience and acceptance such as innovative packaging. Qualifications The selected candidate should have curiosity and strong interest into patient’s knowledge with a clear patient-centric focus, always putting the needs of the patient first. Ideally, the candidate should have experience in developing patient strategies and tactics. In addition to this, the candidate should have an innovative mind-set able to push the boundaries to find the best solutions short term or long term to serve the patient's needs. You have at least 7-10 years of relevant work experience within the pharmaceutical industry and a track record of success. You hold an academic degree in Business Administration, Marketing, Medicine or other relevant degree.
We are looking for a dedicated Senior Global Product Manager to be part of our newly established Oral Semaglutide team. Do you want to be the voice of the patient and to develop our patient strategy? About the department The Oral semaglutide team is part of the GLP-1 Portfolio Corporate Vice President (CVP) area in Strategy, Access & Marketing in Novo Nordisk. Oral semaglutide represents a unique opportunity for Novo Nordisk to enter the large and competitive Oral Anti-diabetic (OAD) market with a product supported by a unique clinical profile. Ahead of the phase III data results in 2018, the oral semaglutide is expanding in preparation of the launch. The position The selected candidate will be the voice of the patient in the Oral Semaglutide team. The candidate will be responsible for developing the patient strategy and tactics for oral semaglutide including product acceptance and experience. This will include definition of patient needs and development of the patient activation strategic framework including patient behavioural segmentation. Further to this, the responsibility in this role will include patient communication strategy and tactics and identification of patient solutions and tools to support product experience and acceptance such as innovative packaging. Qualifications The selected candidate should have curiosity and strong interest into patient’s knowledge with a clear patient-centric focus, always putting the needs of the patient first. Ideally, the candidate should have experience in developing patient strategies and tactics. In addition to this, the candidate should have an innovative mind-set able to push the boundaries to find the best solutions short term or long term to serve the patient's needs. You have at least 7-10 years of relevant work experience within the pharmaceutical industry and a track record of success. You hold an academic degree in Business Administration, Marketing, Medicine or other relevant degree.
The holy grail of oral GLP-1 by diabetes powerhouse Novo? ITCA Killer for sure.
Teva's generic exenatide will soon put pricing pressures on the existing GLP-1 franchises. Patients taking GLP-1 injections are usually on more than 1 med and you can bet that the payers will force the patients to generic once daily then to higher cost once weekly before they very remotely consider ITCA (very long shot!) provided few payers cover "experimental" therapy which payers WILL NOT!
Bye bye ITCA!
Teva's generic exenatide will soon put pricing pressures on the existing GLP-1 franchises. Patients taking GLP-1 injections are usually on more than 1 med and you can bet that the payers will force the patients to generic once daily then to higher cost once weekly before they very remotely consider ITCA (very long shot!) provided few payers cover "experimental" therapy which payers WILL NOT!
Bye bye ITCA!
Working at Intarcia is great preparation for a career as a…
1. Medical Waste Biohazard Cooker
● Speciality: Disposing of medical waste
○ Biohazard Cookers steam bags of medical waste, producing a malodorous aroma
■ The cooking process is steaming bags of bio waste at 260°F for 30 minutes
○ Biohazard bags may contain needles, urine, blood, teeth, semen and other bodily fluids
○ Cookers wear protective gear, but can become contaminated if the gear is punctured
○ The scent of “cooking” is described as a combination of burning rubber, BO and smelly feet
● Average Salary: $16.28/hour
2. Urologist
● Specialty: Urinary tract and male reproductive organs
○ Urologists must be educated in internal medicine, gynecology, pediatrics, male infertility and erectile dysfunction, and other specialties
○ They categorized as surgical sub-specialists
○ Urologists treat a variety of things including:
■ STDs
■ Chronic prostatitis (treatment involves prostate gland massage)
■ Male infertility
■ Kidney stones
■ Hematuria (blood in the urine)
■ Incontinence
● Average Salary: about $461,000
3. Proctologist
● Specialty: the rectum
○ Proctologists examine the anus both visually and manually
○ Often referred to as a colorectal surgeon
○ General practitioners will refer patients to a proctologists when they require surgery for issues related to the colon and rectum
○ They treat constipation, incontinence, fistulas, hemorrhoids, rectal prolapse (the rectum has turned inside out)
● Average Salary: about $407,273
4. Forensic Pathologist
● Specialty: Diagnosing the deceased
○ Forensic pathologists examine those who have had a violent or sudden, unexpected death
○ They determine when, how and why a person has died
○ They may need to be educated not only in medicine, but in
■ Trace evidence
■ DNA technology
■ Firearms
■ Toxicology
■ Blood analysis
○ FPs spend large amounts of time examining tissue samples and performing autopsies
○ Constant exposure to death and violence may have a negative effect on a FPs emotional wellbeing
● Salary: Up to $500,000
5. CTS Decon (Crime and Trauma Scene Decontamination)
● Specialty: Cleaning up after a crime scene
○ This may include the aftermath of murder, suicide, rape, etc.
○ Clean up may include coming in contact with
■ Blood
■ Urine
■ Feces
■ Other body fluids
■ Decomposing bodies
■ Brain matter and more
○ CTS Decon also involves cleanup of chemical contamination
■ Meth labs
■ Anthrax affected sites
○ CTS Decon technicians generally have previous experience in unsavory jobs
■ Often ER nurses or EMTs
● Salary: $40K – $50K
1. Medical Waste Biohazard Cooker
● Speciality: Disposing of medical waste
○ Biohazard Cookers steam bags of medical waste, producing a malodorous aroma
■ The cooking process is steaming bags of bio waste at 260°F for 30 minutes
○ Biohazard bags may contain needles, urine, blood, teeth, semen and other bodily fluids
○ Cookers wear protective gear, but can become contaminated if the gear is punctured
○ The scent of “cooking” is described as a combination of burning rubber, BO and smelly feet
● Average Salary: $16.28/hour
2. Urologist
● Specialty: Urinary tract and male reproductive organs
○ Urologists must be educated in internal medicine, gynecology, pediatrics, male infertility and erectile dysfunction, and other specialties
○ They categorized as surgical sub-specialists
○ Urologists treat a variety of things including:
■ STDs
■ Chronic prostatitis (treatment involves prostate gland massage)
■ Male infertility
■ Kidney stones
■ Hematuria (blood in the urine)
■ Incontinence
● Average Salary: about $461,000
3. Proctologist
● Specialty: the rectum
○ Proctologists examine the anus both visually and manually
○ Often referred to as a colorectal surgeon
○ General practitioners will refer patients to a proctologists when they require surgery for issues related to the colon and rectum
○ They treat constipation, incontinence, fistulas, hemorrhoids, rectal prolapse (the rectum has turned inside out)
● Average Salary: about $407,273
4. Forensic Pathologist
● Specialty: Diagnosing the deceased
○ Forensic pathologists examine those who have had a violent or sudden, unexpected death
○ They determine when, how and why a person has died
○ They may need to be educated not only in medicine, but in
■ Trace evidence
■ DNA technology
■ Firearms
■ Toxicology
■ Blood analysis
○ FPs spend large amounts of time examining tissue samples and performing autopsies
○ Constant exposure to death and violence may have a negative effect on a FPs emotional wellbeing
● Salary: Up to $500,000
5. CTS Decon (Crime and Trauma Scene Decontamination)
● Specialty: Cleaning up after a crime scene
○ This may include the aftermath of murder, suicide, rape, etc.
○ Clean up may include coming in contact with
■ Blood
■ Urine
■ Feces
■ Other body fluids
■ Decomposing bodies
■ Brain matter and more
○ CTS Decon also involves cleanup of chemical contamination
■ Meth labs
■ Anthrax affected sites
○ CTS Decon technicians generally have previous experience in unsavory jobs
■ Often ER nurses or EMTs
● Salary: $40K – $50K
Huh ? WTF ? Sorry once the interviews kept getting delayed and rescheduled I stopped following the story. WTF happened ? How can you take a previously approved drug and a previously approved pump and end up with a CRL ? Is this like the most idiotic laughable story ? OMG ROFL
Huh ? WTF ? Sorry once the interviews kept getting delayed and rescheduled I stopped following the story. WTF happened ? How can you take a previously approved drug and a previously approved pump and end up with a CRL ? Is this like the most idiotic laughable story ? OMG ROFL
That's how royally fucked up Intarcia is. Can't even pass FDA scrutiny for already approved drug exenatide (just off patent) and already approved pump which by the way was pulled from the market due to lack of interest.
Only those unemployed or about to get fired will end up working for Intarcia but there is more - being associated with 1 of the biggest investment scam on par with Theranos and utter launch failure as payors will not pay for multiple pumps and expensive surgeries for SAME drug administered daily/weekly by pt!
The Brad Hendricks Law Firm is reviewing potential claims for people who were prescribed exenatide and were later diagnosed with:
- Pancreatic Cancer
- Thyroid Cancer
- Byetta (Exenatide)
- Victoza (Liraglutide)
- Januvia (Sitagliptin)
- Onglyza (Saxagliptin)
- Tradjenta (Linaglipton)
- Failed to adequately warn about potential side effects, with no mention of pancreatic cancer from exenatide placed on the label;
- Failed to advise physicians about the importance of monitoring for first signs of changes to the pancreas, which may have helped users identify chronic asymptomatic pancreatitis that ultimately led to cancer following exenatide use;
- Failed to sufficiently test Byetta before introducing the diabetes pen, with only a small clinical trial involving only short-term treatment as the basis for approval of the medication, which is now used long-term by many diabetics;
- Failed to issue a exenatide recall after it became apparent that the risks outweigh the benefits provided over other, safer alternative diabetes medications;
Wouldn't impact Intarcia being a shrimp sized wanna be pharma and will run out of money before they launch if they ever get to get of the hole they dug with FDA. If they manage to launch then they will fold within a year due to lack of sales.
Bye bye ITCA!
Bye bye ITCA!
Any insights on Anthera - better choice or same story ? Honest replies only please.
Being here is a cross between lighting yourself on fire twice a day and slamming the car door on your thumb. Some folks are into pain, if that sounds good join us. Please remember we worship our leaders as they are never wrong.
Don't know anything about Anthera pal but stay away from Intarcia. Most of us are miserable, feel cheated and foolish to have left good jobs for this shithole. Many of us are looking to leave once 2017 bonuses are paid. Plenty of DD materials right here so why even ask a stupid question?
Rumor has it the company has enough money till end of 2018 provided that all the remediation work (we're talking about whole new plant) in Hayward stays within the shoe string budget shoved down to Hayward LT throats by KG (remember he is mfg guru too).
Nevermind millions of dollars it claims to have raised as the investor money are tied to meeting important milestone like approval, commercialization, pie in the sky HIV ITCA scam, etc. One of the reason the company filed NDA in 2016 even though it was not close to being ready (and CRL shows it was shoddy work indeed) was to unclock the funds from the investors and more like bagholders. For example, savvy deal Intarcia pulled back in 2015 was $225 million debt deal based future revenue of 1.5% of sales (truly LOL). The investors have the option to convert ti stock (if and when they do an IPO - another LOL). As for IPO - reported to be at least year after FDA approval and poor employees' shares are locked for another year but again highly doubt Intacia will be around in its present form along with ULT a year after launch.
No way in hell they can compete against the existing GLP-1 franchises from the new generics by Teva to all big pharmas and key diabetes players like Novo, Lilly and Sanofi. Add to this Novo's oral GLP-1 expected to complete Ph III trials in mid 2018 and there is NO place for experimental and sky high price ITCAs not to mention surgeries to implant and rip out the old ITCAs. Anyone who has received bills for minor outpatient surgeries know how expensive it can be and add multiple surgeries. BTW - 1 year ITCA does NOT exist but only 3 and 6 months.
Nevermind millions of dollars it claims to have raised as the investor money are tied to meeting important milestone like approval, commercialization, pie in the sky HIV ITCA scam, etc. One of the reason the company filed NDA in 2016 even though it was not close to being ready (and CRL shows it was shoddy work indeed) was to unclock the funds from the investors and more like bagholders. For example, savvy deal Intarcia pulled back in 2015 was $225 million debt deal based future revenue of 1.5% of sales (truly LOL). The investors have the option to convert ti stock (if and when they do an IPO - another LOL). As for IPO - reported to be at least year after FDA approval and poor employees' shares are locked for another year but again highly doubt Intacia will be around in its present form along with ULT a year after launch.
No way in hell they can compete against the existing GLP-1 franchises from the new generics by Teva to all big pharmas and key diabetes players like Novo, Lilly and Sanofi. Add to this Novo's oral GLP-1 expected to complete Ph III trials in mid 2018 and there is NO place for experimental and sky high price ITCAs not to mention surgeries to implant and rip out the old ITCAs. Anyone who has received bills for minor outpatient surgeries know how expensive it can be and add multiple surgeries. BTW - 1 year ITCA does NOT exist but only 3 and 6 months.
No one really knows except the KG and CFO. KG clamped down on spending earlier this year before CRL which does not sound right if the company is flushed with cash. Additional un-budgeted spend to get over the CRL means more cash burn not to mention launch delay.
Suspect money situation may be dire as an outcome of CRL is that no more catered lunches for the lunch meetings. Something I've seen along with travel freeze as precursor to layoffs.
Watch yourselves ! Lots of loose talk can only get you in trouble. You will see a firing THIS WEEK because they complained about KG.
Intarcia announces that Freedom Trial shows Astrazenca’s Drug still works. Dr Julio Rosenstein “It was unethical to put diabetes patients on placebo when we knew that exenatide was an already approved drug but we did it anyway.” Four times as many patients discontinued the disfiguring surgically implanted pump primarily due to GI adverse events. Kurt the Magnificent Overlord of Intarcia said “Making patient undergo surgery to remove the source of their adverse events is really expensive. We hope to make billions. For those who cannot afford the surgery they will be compliant. There is no escape.”